Viz.ai has announced a collaboration with Nico Corporation to improve the lives of patients with intracranial haemorrhages (ICHs), leveraging the former’s artificial intelligence (AI)-powered disease detection and intelligent care coordination products, and the latter’s modern, minimally invasive interventional technologies for neurosurgery.
Through the power of Viz.ai’s technology, hospitals will be able to detect suspected disease earlier and receive accurate volume measurements of brain bleeds that are crucial for assessing the severity of ICH cases. In addition, Nico’s technology can provide early and safe access to the brain with its BrainPath device, and maximal evacuation of the clot with its Myriad device.
The combination of both companies’ technologies will allow for greater efficiencies and enhanced patient care, as stated in a recent press release.
“The results of the ENRICH trial have finally shown positive treatment data on one of the most costly and deadly diseases,” said Chris Mansi, chief executive officer (CEO) and co-founder at Viz.ai. “We’re excited to collaborate with Nico, leveraging our broadly deployed AI platform to assist neurosurgeons in their decision making and improve patient outcomes post ICH.”
The New England Journal of Medicine recently published results from ENRICH, making it—according to Viz.ai’s press release—the first positive trial to improve functional and economic outcomes for ICH. ENRICH demonstrated that early minimally invasive parafascicular surgery (MIPS) intervention using Nico’s BrainPath and Myriad technologies is safe and superior for ICH treatment compared to guideline-based medical management alone, which is the current standard of care.
With the AI-powered Viz ICH Plus module, hospital and health systems can automate the process of identifying, labelling and quantifying the volume of segmentable brain structures on non-contrast computed tomography (NCCT) images. Radiologists, neurologists and neurosurgeons can incorporate Viz ICH Plus seamlessly into their workflows, detect brain bleeds, and automate the manual process of measuring brain bleeds, Viz.ai claims.
“The combination of our patented technologies, the collaboration with Viz.ai and the results of the ENRICH trial are transforming the way that ICH is treated,” said Jim Pearson, president and CEO of Nico. “The AI modules, Viz ICH and Viz ICH Plus, are a welcomed enhancement to patient care by leveraging AI-powered care coordination, getting patients the care they need, when they need it most.”
